RBII — Rising Biosciences Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End null | Unit | null | null | null | null | null | nullE | nullE | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rising Biosciences, Inc. is a research and development company. The Company is focused on oral and topical cannabis and non-cannabis-based pharmaceuticals. The Company operates through three distinct business units. In addition to Oxi Thyme, the second business unit is a physician’s practice management company focused on the proper use of cannabis for the treatment of chronic pain, opioid addiction, and terminal patients. The third business unit is a research and development company focused on oral and topical pharmaceuticals. Through its subsidiaries and investment holdings, the Company is focused on the treatment of individuals in both inpatient and outpatient environments recovering from alcohol and drug addiction.
Directors
- Last Annual
- Last Interim
- Incorporated
- April 29th, 1998
- Public Since
- June 21st, 2001
- Sector
- Media & Publishing
- Industry
- Consumer Cyclicals
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 1,059,725,348
Similar to RBII
Diamond Energy Partners
Pink Sheets on Nasdaq
Ab International
Pink Sheets on Nasdaq
Abv Consulting
Pink Sheets on Nasdaq
Adaptive Ad Systems
Pink Sheets on Nasdaq
Adsouth Partners
Pink Sheets on Nasdaq
FAQ
As of Today at 19:18 UTC, shares in Rising Biosciences are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Rising Biosciences last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Rising Biosciences share price has underperformed the S&P500 Index by -11.77% over the past year.
There is no consensus recommendation for this security.
Rising Biosciences does not currently pay a dividend.
Rising Biosciences does not currently pay a dividend.
Rising Biosciences does not currently pay a dividend.
To buy shares in Rising Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Rising Biosciences had a market capitalisation of .
Here are the trading details for Rising Biosciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: RBII
Based on an overall assessment of its quality, value and momentum Rising Biosciences is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rising Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -13.79%.
As of the last closing price of $0.00, shares in Rising Biosciences were trading -99.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Rising Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Rising Biosciences' directors